Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pentostatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA known ✓ | P00813 | 2/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
| ▸ | PIM1 | P11309 | 1/20 | 0.51 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.51 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.51 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | PNP | P00491 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentostatin SCHEMBL12202591 | 1.00 | ADA (0.57) | ADAADORA3ADORA2AADORA1PIM1 | |
| Pentostatin SCHEMBL14190839 | 1.00 | ADA (0.57) | ADAADORA3ADORA2AADORA1PIM1 | |
| Pentostatin SCHEMBL14514128 | 1.00 | ADA (0.57) | ADAADORA3ADORA2AADORA1PIM1 | |
| Pentostatin SCHEMBL2819465 | 1.00 | ADA (0.57) | ADAADORA3ADORA2AADORA1PIM1 | |
| Pentostatin SCHEMBL7715689 | 1.00 | ADA (0.57) | ADAADORA3ADORA2AADORA1PIM1 | |
| Pentostatin SCHEMBL2353499 | 1.00 | ADA (0.57) | ADAADORA3ADORA2AADORA1PIM1 | |
| Pentostatin SCHEMBL7790216 | 1.00 | ADA (0.57) | ADAADORA3ADORA2AADORA1PIM1 | |
| Pentostatin SCHEMBL14105501 | 1.00 | ADA (0.57) | ADAADORA3ADORA2AADORA1PIM1 | |
| Pentostatin SCHEMBL21133143 | 1.00 | ADA (0.57) | ADAADORA3ADORA2AADORA1PIM1 | |
| Pentostatin SCHEMBL18402543 | 1.00 | ADA (0.57) | ADAADORA3ADORA2AADORA1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 109257 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4747263-A1 | LIPID NANOPARTICLES AND USES THEREOF | University of Connecticut (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260138973-A1 | SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| WO-2026107377-A1 | PHARMACOLOGICAL RE-ACTIVATION OF MUTANT PVHL | KARANICOLAS JOHN (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| EP-4744657-A1 | THERAPEUTIC AGENT FOR HUMAN GRAFT VERSUS HOST DISEASE AND COMBINATION THEREOF | National University Corporation Okayama University (JP) | 2026-05-20 | — | — | EP | claimed |
| WO-2026099502-A1 | NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2026-05-15 | — | — | WO | claimed |
| US-4822736-A | Amplification of adenosine deaminase genes in mammalian cells using adenosine, alanosine, uridine, and deoxycoformycin | BAYLOR COLLEGE OF MEDICINE (US) | 1989-04-18 | — | — | US | claimed |
| EP-0262696-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1988-04-06 | — | — | EP | claimed |
| EP-0262125-A1 | AICA riboside for the prophylactic treatment of diseases with restricted blood flow. | GRUBER HARRY EDWARD | 1988-04-06 | — | — | EP | claimed |
| WO-1987005807-A1 | A METHOD OF INCREASING ADENOSINE EXCRETION | GRUBER HARRY EDWARD | 1987-10-08 | — | — | WO | claimed |
| EP-0222425-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-05-20 | — | — | EP | claimed |
| EP-0221588-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-05-13 | — | — | EP | claimed |
| EP-0218300-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-04-15 | — | — | EP | claimed |
| EP-0110955-A1 | BRAIN-SPECIFIC DRUG DELIVERY. | UNIV FLORIDA (US) | 1984-06-20 | — | — | EP | claimed |
| WO-1983003968-A1 | BRAIN-SPECIFIC DRUG DELIVERY | UNIVERSITY OF FLORIDA (US) | 1983-11-24 | — | — | WO | claimed |
| US-4151347-A | ION EXCHANGE RESINS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1979-04-24 | — | — | US | claimed |